Short- and long-term effect of high versus low-to-moderate intensity exercise to optimise health-related quality of life after oncological treatment-results from the Phys-Can project

被引:7
|
作者
Ax, Anna-Karin [1 ,2 ]
Johansson, Birgitta [3 ]
Lyth, Johan [1 ,2 ]
Nordin, Karin [4 ]
Borjeson, Sussanne [1 ,2 ]
机构
[1] Linkoping Univ, Dept Oncol, Linkoping, Sweden
[2] Linkoping Univ, Dept Hlth Med & Caring Sci, Linkoping, Sweden
[3] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
[4] Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden
基金
瑞典研究理事会;
关键词
Cancer; Oncological treatment; Exercise; HRQoL; EUROPEAN-ORGANIZATION; BREAST-CANCER; FOLLOW-UP; FATIGUE; QUESTIONNAIRE; METAANALYSIS; CHEMOTHERAPY; INSTRUMENT; GUIDELINES; SURVIVORS;
D O I
10.1007/s00520-022-07016-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose This study aimed to evaluate the effect of high intensity (HI) vs low-to-moderate intensity (LMI) exercise on health-related quality of life (HRQoL) up to 18 months after commencement of oncological treatment in patients with breast, colorectal or prostate cancer. In addition, we conducted a comparison with usual care (UC). Methods Patients scheduled for (neo)adjuvant oncological treatment (n = 577) were randomly assigned to 6 months of combined resistance and endurance training of HI or LMI. A longitudinal descriptive study (UC) included participants (n = 89) immediately before the RCT started. HRQoL was assessed by EORTC QLQ-C30 at baseline, 3, 6 and 18 months (1 year after completed exercise intervention) follow-up. Linear mixed models were used to study the groups over time. Results Directly after the intervention, HI scored significant (P = 0.02), but not clinically relevant, higher pain compared with LMI. No other significant difference in HRQoL was found between the exercise intensities over time. Clinically meaningful improvements in HRQoL over time were detected within both exercise intensities. We found favourable significant differences in HRQoL in both exercise intensities compared with UC over time. Conclusion This study adds to the strong evidence of positive effect of exercise and shows that exercise, regardless of intensity, can have beneficial effects on HRQoL during oncological treatment and also for a substantial time after completion of an exercise intervention. In this study, for one year after. Implications for cancer survivors Patients can be advised to exercise at either intensity level according to their personal preferences, and still benefit from both short-term and long-term improvements in HRQoL.
引用
收藏
页码:5949 / 5963
页数:15
相关论文
共 48 条
  • [41] Age-specific health-related quality of life in disease-free long-term prostate cancer survivors versus male population controls-results from a population-based study
    Adam, Salome
    Doege, Daniela
    Koch-Gallenkamp, Lena
    Thong, Melissa S. Y.
    Bertram, Heike
    Eberle, Andrea
    Holleczek, Bernd
    Pritzkuleit, Ron
    Waldeyer-Sauerland, Mechthild
    Waldmann, Annika
    Zeissig, Sylke Ruth
    Jansen, Lina
    Rohrmann, Sabine
    Brenner, Hermann
    Arndt, Volker
    SUPPORTIVE CARE IN CANCER, 2020, 28 (06) : 2875 - 2885
  • [42] Medium to long term health-related quality of life and treatment-related side-effects in patients treated with a single dose of adjuvant carboplatin for high-risk seminoma results from a pilot study
    Cazzaniga, W.
    Pearce, A.
    Tanabalan, C.
    Rajan, P.
    Kinsella, N.
    Reid, A.
    Huddart, R.
    Nicol, D.
    EUROPEAN UROLOGY, 2022, 81 : S849 - S849
  • [43] MEDIUM TO LONG TERM HEALTH-RELATED QUALITY OF LIFE AND TREATMENT-RELATED SIDE-EFFECTS IN PATIENTS TREATED WITH A SINGLE DOSE OF ADJUVANT CARBOPLATIN FOR HIGH-RISK SEMINOMA - RESULTS FROM A PILOT STUDY
    Cazzaniga, Walter
    Pearce, Adam
    Tanabalan, Chandran
    Rajan, Prabhakar
    Kinsella, Netty
    Reid, Alison
    Huddart, Robert
    Nicol, David
    JOURNAL OF UROLOGY, 2022, 207 (05): : E843 - E844
  • [44] Long-term disease-free survival and health-related quality of life results of high-dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer treated in a community cancer center
    William, Raphael
    Mclaughlin, Pierre-Yves
    Pharand-Charbonneau, Mathieu
    Wright, Debbie Smith
    Haddad, Alain
    Gaudet, Marc
    BRACHYTHERAPY, 2025, 24 (01) : 54 - 61
  • [45] Long-term health-related quality of life of breast cancer survivors remains impaired compared to the age-matched general population especially in young women. Results from the prospective controlled BREX exercise study
    Roine, Eija
    Sintonen, Harri
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Penttinen, Heidi
    Utriainen, Meri
    Vehmanen, Leena
    Huovinen, Riikka
    Kautiainen, Hannu
    Nikander, Riku
    Blomqvist, Carl
    Hakamies-Blomqvist, Liisa
    Saarto, Tiina
    BREAST, 2021, 59 : 110 - 116
  • [46] Improvement in Health-Related Quality of Life Measures after Long-Term, Daily, Subcutaneous Concizumab Prophylaxis in Patients with Hemophilia A/B with and without Inhibitors: Results from the Main and Extension Parts of Phase 2 Clinical Trials
    Faller, Mathilde
    Tonder, Sidsel Marie
    Porstmann, Thomas
    BLOOD, 2021, 138
  • [47] Long-term follow-up and health-related quality of life among cancer survivors with stage IEA orbital-type lymphoma after external photon-beam radiotherapy: Results from a longitudinal study
    Hoffmann, Christian
    Rating, Philipp
    Bechrakis, Nikolaos
    Eckstein, Anja
    Sokolenko, Ekaterina
    Jabbarli, Leyla
    Westekemper, Henrike
    Mohr, Christopher
    Schmeling, Claus
    Huettmann, Andreas
    von Tresckow, Julia
    Goericke, Sophia
    Deuschl, Cornelius
    Johansson, Patricia
    Poettgen, Christoph
    Gauler, Thomas
    Guberina, Nika
    Moliavi, Sourour
    Stuschke, Martin
    Guberina, Maja
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (05) : 922 - 929
  • [48] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
    Buehrer, Emanuel
    Kicinski, Michal
    Mandala, Mario
    Pe, Madeline
    Long, Georgina, V
    Atkinson, Victoria
    Blank, Christian U.
    Haydon, Andrew
    Dalle, Stephane
    Khattak, Adnan
    Carlino, Matteo S.
    Meshcheryakov, Andrey
    Sandhu, Shahneen
    Puig, Susana
    Schadendorf, Dirk
    Jamal, Rahima
    Rutkowski, Piotr
    van den Eertwegh, Alfonsus J. M.
    Coens, Corneel
    Grebennik, Dmitri
    Krepler, Clemens
    Robert, Caroline
    Eggermont, Alexander
    LANCET ONCOLOGY, 2024, 25 (09): : 1202 - 1212